Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) Shares Outstanding (Weighted Average) (2016 - 2021)

GT Biopharma (GTBP) has disclosed Shares Outstanding (Weighted Average) for 12 consecutive years, with $31.4 million as the latest value for Q3 2021.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 595.27% to $31.4 million in Q3 2021 year-over-year; TTM through Sep 2021 was $31.4 million, a 595.27% increase, with the full-year FY2020 number at $4.4 million, changed N/A from a year prior.
  • Shares Outstanding (Weighted Average) was $31.4 million for Q3 2021 at GT Biopharma, up from $24.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $54.0 million in Q3 2019 to a low of -$22.42 in Q2 2017.
  • A 5-year average of $23.7 million and a median of $16.2 million in 2021 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 100.0% in 2017, then skyrocketed 223541478.23% in 2018.
  • GT Biopharma's Shares Outstanding (Weighted Average) stood at $16769.0 in 2017, then skyrocketed by 298990.68% to $50.2 million in 2018, then rose by 7.6% to $54.0 million in 2019, then tumbled by 91.87% to $4.4 million in 2020, then soared by 615.61% to $31.4 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Shares Outstanding (Weighted Average) are $31.4 million (Q3 2021), $24.9 million (Q2 2021), and $16.2 million (Q1 2021).